Mechanism of action
Drug category
Drug
Reuptake inhibition
Antidepressant
• SSRI
Fluoxetine, paroxetine, sertraline, citalopram, escitalopram
• SNRI
Venlafaxine, desvenlafaxine, duloxetine
• DNRI
Bupropion
• TCA
Amitriptyline, nortriptyline, clomipramine, desipramine, doxepin
• Serotonin modulator
Trazodone
Others
1. Antiepileptic—valproate, carbamazepine
2. Antiemetic—ondansetron, metoclopramide
3. Bariatric—sibutramine
4. Muscle relaxant—cyclobenzaprine
5. Amphetamine — dextromethorphan
6. Analgesic—meperidine, tramadol
7. Supplement—St. John’s wort, ginseng
8. Illicit—cocaine, MDMA
Serotonin metabolism inhibition
MAOI
• Antidepressants
Phenelzine, selegiline, isocarboxazid
• Antimicrobials
Linezolid
• Others
Methylene blue
Increases serotonin release
Amphetamine
Dextromethorphan, methamphetamine
Parkinsonian
Levodopa, carbidopa-levodopa
Illicit
Cocaine, MDMA
Increases serotonin formation
Amino acid
Tryptophan
Direct serotonin agonist
Antimigraine
1. Triptans—sumatriptan, rizatriptan
2. Ergots—ergotamine, methylergonovine
Analgesic
Fentanyl
Illicit
LSD
Increases sensitivity at postsynaptic receptor
Antipsychotic
Lithium
The clinical presentation is classically described as a triad of cognitive/behavioral changes (confusion, agitation, lethargy, coma), autonomic instability (hyperthermia, tachycardia, diaphoresis, nausea, vomiting, diarrhea, dilated pupils), and neuromuscular changes (myoclonus, hyperreflexia, rigidity, trismus) [13]. It is known to vary on a spectrum ranging from mild to moderate to severe including death [2]. Several sets of diagnostic criteria have been developed to define serotonin syndrome, including the Sternbach criteria [2] and the Hunter Criteria [14] (Box 9.1). In a study of the Hunter Criteria , the clinical findings that have been shown to have a statistically significant association were clonus (inducible, ocular, spontaneous), myoclonus, hyperreflexia, peripheral hypertonicity, and shivering [14]. The onset of symptoms is typically rapid; approximately 75% of patients with serotonin syndrome present within 24 h after initial use of medication, an overdose, or a change in dosing [13]. However, administration of a serotonergic agent within 5 weeks after the discontinuation of fluoxetine has been shown to initiate serotonin syndrome [15]. It does not resolve spontaneously unless the causative agents are discontinued.
Box 9.1 Comparison of Serotonin Syndrome Diagnostic Criteria
Sternbach criteria—1991 | Hunter serotonin toxicity criteria—2003 |
---|---|
Recent addition or increase in dosage of a known serotonergic agent
Full access? Get Clinical TreeGet Clinical Tree app for offline access |